









Markets
/
Stocks
/
nasdaq-anip
/

ANI Pharmaceuticals Inc

ANIP

97.480USD

+2.125+2.23%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

2.12BMarket Cap

LossP/E TTM



ANI Pharmaceuticals Inc

97.480

+2.125+2.23%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

9 / 175

Overall Ranking

62 / 4721

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

103.571

Target Price

+8.62%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset, Purified Cortrophin Gel, as well as its generics business with enhanced research and development capabilities. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of approximately 118 products with a variety of indications and a robust portfolio of pipeline products.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 94.19% year-on-year.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD 20.15M.%!(EXTRA int=2)

Undervalued

The company’s latest PE is -142.53, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 24.45M shares, decreasing 4.47% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.27M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.66.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 9.09, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 211.37M, representing a year-over-year increase of 53.12%, while its net profit experienced a year-over-year increase of 371.83%.

Score

Industry at a Glance

Previous score

9.09

Change



Financials

7.66

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.80

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -139.42, which is -128.39% below the recent high of 39.58 and 58.61% above the recent low of -57.71.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 9/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.50, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for ANI Pharmaceuticals Inc is 100.00, with a high of 121.00 and a low of 77.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

103.571

Target Price

+8.62%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

ANI Pharmaceuticals Inc

ANIP

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 8.78, which is higher than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 100.15 and the support level at 89.90, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.78

Change

0.38

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-1.554

Neutral

RSI(14)

66.904

Neutral

STOCH(KDJ)(9,3,3)

55.618

Neutral

ATR(14)

2.483

High Vlolatility

CCI(14)

25.560

Neutral

Williams %R

26.844

Buy

TRIX(12,20)

0.783

Sell

StochRSI(14)

29.193

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

97.381

Buy

MA10

97.211

Buy

MA20

94.970

Buy

MA50

81.525

Buy

MA100

72.784

Buy

MA200

66.594

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 112.92%, representing a quarter-over-quarter increase of 1.03%. The largest institutional shareholder is The Vanguard, holding a total of 1.27M shares, representing 5.87% of shares outstanding, with 5.87% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

2.44M

-3.53%

The Vanguard Group, Inc.

Star Investors

1.18M

-10.14%

Meridian Venture Partners

1.16M

-17.97%

Millennium Management LLC

1.12M

+36.45%

Global Alpha Capital Management Ltd.

735.59K

+17.78%

State Street Global Advisors (US)

714.57K

-3.08%

Deep Track Capital LP

700.00K

+7.85%

Esjay L.L.C,

632.62K

-24.02%

Citadel Advisors LLC

723.33K

+22.27%

Dimensional Fund Advisors, L.P.

631.56K

-7.90%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 5.93, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.59. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.